Compare Amazon.com Inc (AMZN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs BIO-TECHNE Corp — how do they compare? Amazon.com Inc trades at $272.2 (market cap $3.00T), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Amazon.com Inc is far larger — about 266.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | TECH | |
|---|---|---|
Market Cap | $3.00T | $11.24B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $72.29 |
52-Week Low | $198.79 | $43.31 |
Enterprise Value | $3.10T | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $272.27, down 0.81% in the last session, with a bullish technical outlook supported by moving averages and strong support at $268. The company reported robust fundamentals with 2025 revenue of $716.92 billion, net income of $77.67 billion, and a 17.44% net margin, while recent earnings beats in Q1 and Q2 2026 highlight growth momentum. News coverage remains positive, focusing on AI initiatives and AWS expansion as key drivers.
The stock presents a compelling opportunity with an 89% analyst buy rating and a $333.86 consensus price target, implying significant upside. Risks include intense competition in e-commerce and cloud services, high capital expenditures, and macroeconomic sensitivity. Investors should weigh strong cash flow generation against valuation multiples like a P/E of 22.37 for balanced decision-making.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
